Hodgkin Lymphoma
Conditions
Keywords
Hodgkin lymphoma, Elderly patients, Real-world data, Prognostic model
Brief summary
This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives. The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.
Interventions
None listed
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥60 years * Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma * Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy * Availability of complete clinical, pathological, and follow-up data
Exclusion criteria
* Presence of other malignant tumors * Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate \<30 mL/min) * Missing more than 20% of required clinical data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From date of diagnosis until death from any cause, assessed up to 60 months. | Overall survival (OS) is defined as the time from diagnosis to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-Free Survival (DFS) | From date of first documented remission until disease relapse or death from any cause, whichever occurs first, assessed up to 60 months. | Disease-free survival (DFS) is defined as the time from remission to disease relapse or death from any cause. |
| Progression-Free Survival (PFS) | From date of diagnosis until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 60 months. | Progression-free survival (PFS) is defined as the time from diagnosis to disease progression or death from any cause. |
| Event-Free Survival (EFS) | From date of diagnosis until treatment failure, disease relapse, or death from any cause, whichever occurs first, assessed up to 60 months. | Event-free survival (EFS) is defined as the time from diagnosis to treatment failure, disease relapse, or death from any cause. |
| Proportion of Participants With Disease Progression or Death Within 24 Months From Diagnosis (POD24) | From date of diagnosis to 24 months after diagnosis. | Progression of disease within 24 months (POD24) is defined as the occurrence of documented disease progression or death from any cause within 24 months from the date of diagnosis. |
Countries
China
Outcome results
None listed